Kristi Rosa

Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Nogapendekin alfa inbakicept MAAs have been submitted to the EU's EMA and the UK's MHRA for BCG-unresponsive non–muscle-invasive bladder cancer.

OST-HER2 shows promise in patients with recurrent, fully resected lung-only metastatic osteosarcoma.

Tisotumab vedotin led to improved survival vs chemotherapy in a Chinese subpopulation of previously treated cervical cancer enrolled in innovaTV 301.

Sunvozertinib gets priority review in EGFR-mutated NSCLC, iparomlimab/tuvonralimab combination elicits responses in cervical cancer, and more.

Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.

An acalabrutinib triplet elicited a high response rate in patients with de novo mantle cell lymphoma.

An investigative JAK2 inhibitor demonstrated acceptable tolerability and early clinical activity in patients with JAK inhibitor–naive myelofibrosis.

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.

Neoadjuvant camrelizumab paired with chemotherapy significantly improved pCR over chemotherapy alone in early or locally advanced TNBC.

Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.

Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.

Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.

Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.

Fruquintinib plus sintilimab injection has received conditional approval from the NMPA for mismatch repair–proficient advanced endometrial cancer.